Soliris (eculizumab) Inhibits TMA and Improves Renal Function in Pediatric and Adult Patients with atypical Hemolytic Uremic Syndrome

11-11-2013 Business Wire HealthComments (0)

Alexion PharmaceuticalsPharmaceuticalSoliris

Alexion announced that researchers presented data from four Phase 2 clinical trials and one global registry, all demonstrating the clinical benefits of Soliris® for the treatment of aHUS at ASN

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top